RLH Capital’s Drugs Made In America Acquisition Corp DMAA Stock Holding History
Bought
Maintained
Sold
Other funds holding DMAA
RLH Capital's DMAA Position: Q2 2026 in Review
RLH Capital reduced its Drugs Made In America Acquisition Corp (DMAA) stake by 63% in Q2 2026, selling an estimated $2.13M and leaving 115,606 shares worth $1.23M. The position accounts for 0.59% of the portfolio, ranked #53.
RLH Capital first reported a position in DMAA in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.32M in Q1 2026. 23 funds tracked by Wall St. Rank hold DMAA as of Q2 2026.
- RLH Capital held 115,606 shares of Drugs Made In America Acquisition Corp worth $1.23M as of Q2 2026.
- RLH Capital sold 200,945 Drugs Made In America Acquisition Corp shares in Q2 2026, an estimated $2.13M.
- Drugs Made In America Acquisition Corp made up 0.59% of RLH Capital's portfolio in Q2 2026, its #53 holding.
- RLH Capital first reported a position in Drugs Made In America Acquisition Corp in Q1 2026 and has held it in 2 quarters since.
- RLH Capital's Drugs Made In America Acquisition Corp position peaked at $3.32M in Q1 2026.
- 23 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q2 2026.
Based on RLH Capital's 13F filing for Q2 2026, filed 10 Aug 2026.